HS-20093 for Injection

Phase 2

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JHPCY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Aug '27

JHPCYPDUFA$45.1B

Phase 2

FDA PDUFA Date AP301

HS-20093 for Injection• Prostate Cancer

Aug 2027~ConfirmedSTALE

Source

00%

Competitive Landscape

7 competitors in Prostate Cancer

CADLaglatimagene besadenovec

Phase 3

CASIPanzem® NCD

Phase 2

SNYCabazitaxel XRP6258

Drug Information

Target Indication

Prostate Cancer

Clinical Trial

NCT07230106

Last updated: 3/5/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

JHPCY

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Biotechnology•North America•NASDAQ

Related Pipeline

apatinibPhase 3

Non-Small-Cell Lung Cancer

SHR6390Phase 3

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

SHR-1209Phase 3

Primary Hypercholesterolemia

PyrotinibPhase 3

HER2-positive Breast Cancer

SHR-1210Phase 3

Nasopharyngeal Carcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts